Cytosorbents (CTSO) Retained Earnings (2010 - 2026)

Cytosorbents (CTSO) has reported Retained Earnings for 17 consecutive years, with $321.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 0.91% year-over-year to $321.9 million; the trailing twelve-month figure through Jun 2026 stood at $321.9 million (up 0.91% YoY), and the FY2025 full-year result was $321.0 million, up 3.29% from the prior year.
• Retained Earnings steadied at $321.9 million in Q2 2026 per CTSO's latest filing, from $321.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at $321.9 million in Q2 2026 and bottomed at $284.0 million in Q1 2022.
• Historically, Retained Earnings has averaged $304.4 million across 5 years, with a median of $308.0 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings gained 6.69% in 2023, then climbed 0.91% in 2026.
• Over 5 years, Retained Earnings stood at $287.0 million in 2022, then rose by 6.69% to $306.2 million in 2023, then rose by 1.51% to $310.8 million in 2024, then rose by 3.29% to $321.0 million in 2025, then grew by 0.28% to $321.9 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $321.9 million, $321.6 million, and $321.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.